Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China

Autor: Zhiqiang Wang, Zhibo Zhang, Yong Li, Li Sun, Dezhen Peng, Danyu Du, Xian Zhang, Luwei Han, Liwen Zhao, Ligong Lu, Hongzhi Du, Shengtao Yuan, Meixiao Zhan

Publikováno v: Acta Pharmaceutica Sinica B, Vol 11, Iss 6, Pp 1526-1540 (2021)

Acute myeloid leukaemia (AML) is the most common form of acute leukaemia in adults, with increasing incidence with age and a generally poor prognosis. Almost 20% of AML patients express mutant isocitrate dehydrogenase 2 (mIDH2), which leads to the ac

Externí odkaz: https://doaj.org/article/e33fabccea1f46cc8d7aca7e5c48fa8b

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Exploration of natural product database for the identification of potent inhibitor against IDH2 mutational variants for glioma therapy.

Autor: Murali P; Department of Biotechnology, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India., Karuppasamy R; Department of Biotechnology, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India. kramanathan@vit.ac.in.

Publikováno v: Journal of molecular modeling [J Mol Model] 2022 Dec 09; Vol. 29 (1), pp. 6. Date of Electronic Publication: 2022 Dec 09.